Hudson Bay Capital Management’s Kura Oncology KURA Stock Holding History

Hudson Bay Capital Management’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-75,000	Closed	-$1.08M	–	815
2023 Q4	$1.08M	Buy	+75,000	New	+$737K	0.01%	512
2023 Q2	–	Sell	-205,000	Closed	-$2.51M	–	926
2023 Q1	$2.51M	Buy	+205,000	New	+$2.56M	0.02%	483
2022 Q3	–	Sell	-45,000	Closed	-$825K	–	1293
2022 Q2	$825K	Hold	45,000	–	–	0.01%	954
2022 Q1	$724K	Sell	45,000 -11,632	-21%	-$168K	0.01%	854
2021 Q4	$793K	Sell	56,632 -48,368	-46%	-$784K	0.01%	824
2021 Q3	$1.97M	Buy	105,000 +25,000	+31%	+$471K	0.03%	627
2021 Q2	$1.67M	Buy	+80,000	New	+$1.99M	0.02%	659
2018 Q4	–	Sell	-95,103	Closed	-$1.66M	–	850
2018 Q3	$1.66M	Buy	95,103 +25,103	+36%	+$481K	0.02%	499
2018 Q2	$1.27M	Buy	70,000 +20,000	+40%	+$339K	0.02%	601
2018 Q1	$938K	Buy	+50,000	New	+$973K	0.02%	583

Other funds holding KURA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Hudson Bay Capital Management's KURA Position: Q1 2024 in Review

Hudson Bay Capital Management sold out of Kura Oncology (KURA) in Q1 2024, closing a stake of 75,000 shares — an estimated $1.08M sold.

Hudson Bay Capital Management first reported a position in KURA in Q1 2018 and held it in 10 quarters. The position peaked at $2.51M in Q1 2023. 165 funds tracked by Wall St. Rank hold KURA as of Q1 2024.

Hudson Bay Capital Management reported no remaining Kura Oncology position as of Q1 2024 after selling out during the quarter.
Hudson Bay Capital Management sold 75,000 Kura Oncology shares in Q1 2024, an estimated $1.08M.
Hudson Bay Capital Management first reported a position in Kura Oncology in Q1 2018 and held it in 10 quarters.
Hudson Bay Capital Management's Kura Oncology position peaked at $2.51M in Q1 2023.
165 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2024.

Based on Hudson Bay Capital Management's 13F filing for Q1 2024, filed 15 May 2024.